Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 8/20 | 0.74 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.74 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.74 |
| ▸ | MRGPRX2 | Q96LB1 | 4/20 | 0.74 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.74 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.74 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.74 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.66 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.66 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1278380 | 1.00 | OPRD1 (0.74) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL24880 | 1.00 | OPRD1 (0.74) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL678993 | 1.00 | OPRD1 (0.74) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL15249248 | 1.00 | OPRD1 (0.74) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Hydrochloric Acid SCHEMBL31058090 | 0.99 | OPRD1 (0.73) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Propionic Acid SCHEMBL28993771 | 0.95 | OPRD1 (0.67) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL16866229 | 0.95 | OPRM1 (0.66) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL23673341 | 0.91 | OPRD1 (0.71) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL31298539 | 0.91 | OPRM1 (0.76) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL27557540 | 0.90 | OPRD1 (0.67) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3682872-B1 | LIQUISOFT CAPSULES | PATHEON SOFTGELS INC (US) | 2024-01-03 | — | — | EP | claimed |
| EP-3064199-B1 | ABUSE-DETERRENT TRANSDERMAL FORMULATIONS OF OPIATE AGONISTS AND AGONIST-ANTAGONISTS | BUZZZ PHARMACEUTICALS LTD (IE) | 2023-12-20 | — | — | EP | claimed |
| EP-3313407-B1 | TREATMENT AND MANAGEMENT OF AUGMENTATION IN RESTLESS LEGS SYNDROME | UNIV EAST CAROLINA (US) | 2023-07-19 | — | — | EP | claimed |
| EP-3385252-B1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARM INC (US) | 2022-09-21 | — | — | EP | claimed |
| EP-3291676-B1 | MITRAGYNINE ANALOGS AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-08-17 | — | — | EP | claimed |
| CN-118632835-A | Tryptamine compositions and methods | 赛本爱尔兰有限公司 | 2024-09-10 | — | — | CN | disclosed |
| CN-118234708-A | Formulations of nudity alkali analogs and methods of use | 赛本爱尔兰有限公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-115666653-A | Antibody-drug conjugates | 斯皮雷亚有限公司 | 2023-01-31 | — | — | CN | disclosed |
| CN-111314876-B | System and method for emission and continuous monitoring of analyte values | 德克斯康公司 | 2022-12-30 | — | — | CN | disclosed |
| EP-1765303-B2 | ORAL TABLET SAFEGUARDED AGAINST ABUSE | GRUENENTHAL GMBH (DE) | 2022-11-23 | — | — | EP | disclosed |
| US-20220023260-A1 | Ready to Use Ketorolac Formulations | RTU PHARMACEUTICALS, LLC | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220023260-A1 | Ready to Use Ketorolac Formulations | KHK, VKORC1, PROKR1 | OPRD1 116/4885OPRM1 207/4885OPRK1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.